Johnson & Johnson (JNJ)vsSyndax Pharmaceuticals Inc (SNDX)
JNJ
Johnson & Johnson
$271.22
+0.20%
HEALTHCARE · Cap: $648.67B
SNDX
Syndax Pharmaceuticals Inc
$18.20
+1.28%
HEALTHCARE · Cap: $1.61B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 38722% more annual revenue ($97.93B vs $252.25M). JNJ leads profitability with a 21.5% profit margin vs -87.5%. JNJ earns a higher WallStSmart Score of 59/100 (C).
JNJ
Buy59
out of 100
Grade: C
SNDX
Avoid31
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 25 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 29.2%
Generating 3.4B in free cash flow
Revenue surging 91.8% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Expensive relative to growth rate
Earnings declined 0.9%
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
Trading at 107.1x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.5% and operating margin at 29.2%.
Bull Case : SNDX
The strongest argument for SNDX centers on Revenue Growth. Revenue growth of 91.8% demonstrates continued momentum.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, Piotroski F-Score, PEG Ratio.
Bear Case : SNDX
The primary concerns for SNDX are EPS Growth, Market Cap, Piotroski F-Score. Debt-to-equity of 39.03 is elevated, increasing financial risk.
Key Dynamics to Monitor
JNJ profiles as a mature stock while SNDX is a hypergrowth play — different risk/reward profiles.
SNDX carries more volatility with a beta of 0.37 — expect wider price swings.
SNDX is growing revenue faster at 91.8% — sustainability is the question.
JNJ generates stronger free cash flow (3.4B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (59/100 vs 31/100), backed by strong 21.5% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Syndax Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. The company is headquartered in Waltham, Massachusetts.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?